Tag «GlaxoSmithKline»

FDA approves first treatment Benlysta (belimumab) for pediatric patients with lupus

It’s only fair to share…   The U.S. Food and Drug Administration today approved Benlysta (belimumab) intravenous (IV) infusion for treatment of children with systemic lupus erythematosus (SLE) – often referred to as simply “lupus” – a serious chronic disease that causes inflammation and damage to various body tissues and organs. This is the first …

Daprodustat, ダプロデュスタット

It’s only fair to share… Daprodustat, GSK1278863 ダプロデュスタット CAS 960539-70-2 GSK1278863; GSK 1278863; GSK-1278863; Daprodustat C19H27N3O6 Exact Mass: 393.18999 (1,3-dicyclohexyl-2,4,6-trioxohexahydropyrimidine-5-carbonyl)glycine N-[(l,3-dicyclohexyl-6-hydroxy-2,4-dioxo-l,2,3,4- tetrahydro-5-pyrimidinyl)carbonyl]glycine 2-(1,3-dicyclohexyl-2,4,6-triohexahydropyrimidine-5-carboxamide acetic acid Mechanism of Action: HIF-prolyl hydroxylase inhibitor Indication: anemia, diabetic wounds, and reduction of ischemic complications Development Stage: Phase II Developer:GlaxoSmithKline UNII:JVR38ZM64B ダプロデュスタット Daprodustat C19H27N3O6 : 393.43 [960539-70-2] Daprodustat , also known as …

TAFENOQUINE, タフェノキン

It’s only fair to share… Tafenoquine タフェノキン N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- 106635-80-7 [RN] 262P8GS9L9 7835 N4-{2,6-Dimethoxy-4-methyl-5-[3-(trifluormethyl)phenoxy]-8-chinolinyl}-1,4-pentandiamin WR-238605, WR 238605, cas no 106635-80-7, Tafenoquine succinate, Etaquine, SB-252263, WR-238605 N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine Molecular Formula: C24H28F3N3O3 Molecular Weight: 463.49263 Medicines for Malaria Venture Walter Reed Army Institute (Originator) PATENT  US 4617394 Synonyms Etaquine[5] WR 238605 [5] SB-252263 New Drug Application (NDA): 210795 Company: GLAXOSMITHKLINE FDA approved on July 20, 2018 FDA …

REMOGLIFLOZIN ETABONATE

It’s only fair to share… REMOGLIFLOZIN ETABONATE 5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside, ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-oxan-2-yl]methyl carbonate  https://clinicaltrials.gov/show/NCT02537470   UNII:TR0QT6QSUL CAS 442201-24-3 189075  BHV-091009  GSK-189075  GSK-189075A  KGT-1681  BHV Pharma  Kissei (Originator)  , GlaxoSmithKline Remogliflozin etabonate Phase II A SGLT-2 antagonist potentially for the treatment of type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity. GSK-189075; GSK-189075A Molecular FormulaC26H38N2O9 Average mass522.588 Remogliflozin etabonate (INN/USAN)[1] …